Hisamitsu Pharmaceutical Co., Ltd, a subsidiary of Hisamitsu Pharmaceutical Co., Inc., is a Taiwanese company located in Taipei. The firm manufactures and markets pharmaceuticals.

Teikoku Seiyaku Co. Ltd. manufactures and distributes pharmaceuticals. It offers poultices, including Lidoderm, medicated patches and plasters, and anti-inflammatory plasters. The company also provides prescription drugs, such as Dovonex ointment, Hap Star ID, Glycerin Enema, Steronema, Bari-Enema, Magtect U, and Zikilion syrups. Teikoku Seiyaku was founded in 1848 and is headquartered in Higashi Kagawa, Japan

SmithKline Beecham (Cork) Ltd., part of GSK Plc, is an Irish company located in Carrigaline that manufactures pharmaceutical products.

Pharmacia & Upjohn Co. LLC, a subsidiary of Pfizer Inc., is a company headquartered in Bingham Farms, MI, that manufactures and supplies pharmaceutical goods.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended-release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive-compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome.

HEXAL is the German generic manufacturer and belongs to the worldwide Sandoz Group with its headquarters in Holzkirchen, Bavaria. HEXAL brings biosimilars to the German market. Biosimilars are high-differentiated products, based on very complex biological molecules. Biologics, or biopharmaceuticals, are medicines produced from living organisms using biotechnology techniques. Many biologics are recombinant proteins and are manufactured using „recombinant DNA“ technology, a process that involves inserting a specific gene into a host cell to produce a particular protein. These complex state-of-the-art molecules represent a distinct regulatory class of medicine compared to traditional, chemically synthesized medicines. In Germany HEXAL employs more then 4.000 people at six sites. The company was founded in 1986 and merged with Sandoz in 2006.

USV Private Limited is a 55 year old leading healthcare company which began as a joint venture with USV&P Inc. USA, a subsidiary of Revlon. Their product offering today includes Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in our cGMP compliant plants located in India.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Zhejiang Huahai Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products. It also integrates and intermediates formulations such as Active Pharmaceutical Ingredients. Its products include Irbesartan and Hydrochlorothiazide Tablet, Paroxetine Hydrochloride Tablet and Irbesartan Tablet. The company was founded in 1989 and is headquartered in Zhejiang, China.

Pharmathen SA develops, manufactures, and markets pharmaceuticals. Its products include a-cnotren, adicanil, alcinin, atostana, aurid, azapin, belifax, calci-10, deprevix cr, esmocard, farbovil, faxiven, depilonine pro, depilonine cream, aripiprazole, atorvastatin, brinzolamide, caspofungin, and clopidogrel. The company was founded in 1969 and is headquartered in Pallini, Greece.

It is a biopharmaceutical company that researches and develops advanced new type pharmaceuticals / cosmetics . Drug delivery systems that they intensively research and develop are transdermal delivery formulations Patient-friendly administration through the route of administration and formulation modification of existing oral agents It is a patch formulation. They have world-class skin permeation enhancement technology, various patch structure design technology, They supply products to domestic and overseas partners based on drug release control technology and manufacturing process technology. They have world-class skin permeation enhancement technology, various patch structure designing technology, drug release control technology and manufacturing process technology based on innovative research and development aiming first-in-class. Pharmaceutical KGMP production facility, after strict process control and quality inspection, produce medicinal products and supply products to domestic and overseas partners. ICEQUE Co., Ltd. is committed to the improvement of quality of life through the development of new drugs They are doing their best to grow into a global company.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Zhejiang Huahai Licheng Pharmaceutical Co., Ltd., established on 2016-06-06, Business scope includes licensed projects:pharmaceutical production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Chemical product production(No licensed chemical products);Import and export;Technology Import and Export(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

WHANIN Pharmaceutical is a pharmaceutical company that develops, manufactures, markets, and sells the therapeutic products. WHANIN originally focused on the psychiatric and neurological diseases. Recognizing new opportunities in CNS disorders, WHANIN is concentrating on bringing the new products and technologies for the patients suffering from such CNS disorders. During the past quarter of the century in the healthcare professionals and Korean community, WHANIN is engraved as one of the best local pharmaceutical companies which dedicates to supplying the social and medical communities with the quality products.

Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.

Smith Kline & French Laboratories Ltd. manufactures pharmaceutical products. The company is headquartered in Brentford, the United Kingdom.

Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The firm operates through In India and Outside India geographical segments. Its products include API's and impurities. The firm supplies active pharmaceutical ingredients to pharmaceutical companies and also provides research and development services. The company was founded on January 4, 1995 and is headquartered in Manimajra, India.

Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders. Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations. The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties. Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes. Finally, Titan is also entitled to royalty revenue of 8-10% of net sales of Fanapt® (iloperidone), an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG (“Novartis”) under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension). Substantially all of this future royalty revenue has been sold to Deerfield Management (“Deerfield”), a healthcare investment fund, in exchange for cash and debt considerations which have been used to advance the development of Probuphine and for general corporate purposes.